Free Trial
NASDAQ:SLS

SELLAS Life Sciences Group Q4 2024 Earnings Report

SELLAS Life Sciences Group logo
$1.78 +0.16 (+9.57%)
As of 03:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SELLAS Life Sciences Group EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.03
One Year Ago EPS
-$1.34

SELLAS Life Sciences Group Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

SELLAS Life Sciences Group Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 20, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

SELLAS Life Sciences Group's Q1 2025 earnings is scheduled for Tuesday, May 13, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

SELLAS Life Sciences Group Earnings Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More SELLAS Life Sciences Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like SELLAS Life Sciences Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SELLAS Life Sciences Group and other key companies, straight to your email.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group (NASDAQ:SLS), a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

View SELLAS Life Sciences Group Profile

More Earnings Resources from MarketBeat